Factors associated with dropout and noncompliance in patients with schizophrenia: Results of a one-year follow-up

Clinical Schizophrenia and Related Psychoses

Volumn 1, Issue 2, 2007, Pages 161-167

  Üçok, Alp ^a   Yazici, Kazim ^b   Mete, Levent ^c   Kültür, Savaş ^c   Gogus A ^d   Erkoç, Köahap ^e   Alptekin, Köksal ^f  

^a ISTANBUL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c Izmir Atatürk State Hospital   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e Bakirköy State Hospital of Mental Disorders   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Antipsychotics; Compliance; Dropout; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG SAFETY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RATING SCALE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

EID: 67649752219     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.1.2.5     Document Type: Article

References (25)

1. Martin JL, Perez V, Sacristan M, Rodriguez-Artalejo F, Martinez C, Alvarez E. Meta-analysis of dropout rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry 2006;21:11-20.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al; Clinical Antipsychotic Trials of Intervention Efectiveness (CATIE) Investigators. Efectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
3. Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with frst-episode schizophrenia, schizophreniform and schizoafective disorder. Eur Psychiatry 2002;17:148-154.
4. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a frst episode of schizophrenia or schizoafective disorder. Arch Gen Psychiatry 1999;56:241-247.
5. Marder SR. Overview of partial compliance. J Clin Psychiatry 2003;63(Suppl 16):3-9.
6. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication infuences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310.
7. Fleischhacker WW, Oehl MA, Hummer M. Factors infuencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl 16):10-13.
8. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001;155:230-233.
9. Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, et al. Pharmacological long-term treatment strategies in frst episode schizophrenia - study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254:129-140.
10. Ucok A, Polat A, Cakir S, Genc A. One year outcome in frst episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006; 256:37-43.
11. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54:719-723.
12. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-667.
13. Santariasci B, Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother 2003;37:556-563.
14. Lukof D, Nuechterlein KH, Ventura J. Manual for the expanded Brief Psychiatric Rating Scale (BPRS). Schizophr Bull 1986;13:261-276.
15. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Dept. Of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. Te UKU side efect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side efects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
17. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ter 1998;20:764-771.
18. Ellis AE, Gogel R P, Roman BR, Watson JB, Indyk D, Rosenberg G. Te STARK study: a cross-sectional study of adherence to short-term drug regiments in urban Kenya. Soc Work Health Care 2006;42:237-250.
19. Alptekin K, Erkoc S, Gogus AK, Kultur S, Mete L, Ucok A, et al. Disability in schizophrenia : clinical correlates and prediction over 1-year follow-up. Psychiatry Res 2005;135:103-111.
20. Marder SR, Mebane A, Chien CP, Winslade WJ, Swann E, Van Putten T. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983;140:470-472.
21. Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A, et al. A prospective evaluation of adherence to medication in frst episode schizophrenia. Eur Psychiatry 2006;21:29-33.
22. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychot- ics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17:65-68.
23. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
24. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003;64(Suppl 16):34-40.
25. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(Suppl 16):24-33.